1. Scrip
  2. >>Business
  3. >>Deals

MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration

 
• By Joseph Haas

The AstraZeneca affiliate and the Boston-area synthetic biology specialist are creating a spinout to develop a bispecific antibody targeting Ang2 and VEGF for undisclosed indications. Cancer and wet age-related macular degeneration seem likely areas of focus.

Possibly reflecting a tightening of focus at MedImmune LLC, the biologics division of AstraZeneca PLC announced an agreement Nov. 29 with Abpro Labs to co-develop a preclinical bispecific antibody that targets both angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF). No financial terms were disclosed and the companies aren’t talking about specific indications for the MedImmune-discovered antibody.

The agreement will establish a spinout called AbMed, to be operated on a day-to-day basis by Woburn, Mass.-headquartered Abpro, whose focus is on synthetic biology

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.